Physician profile
James B Cooper
NPI 1437284189
$6,441.45
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,363 · 2020: $1,703 · 2021: $2,194 · 2022: $81.83 · 2023: $33.58 · 2024: $66.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $99.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $99.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $827.43 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $776.77 | 2019-2021 | |
| Pfizer INC. | $452.04 | 2019-2021 | |
| Astellas Pharma US INC | $361.54 | 2019-2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $356.68 | 2019-2021 | |
| Abbvie INC. | $352.87 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $330.33 | 2019-2021 | |
| Amgen INC. | $297.55 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $294.57 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $288.78 | 2019-2021 | |
| Amarin Pharma, INC. | $252.86 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $248.50 | 2021 | |
| Novo Nordisk INC | $209.79 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $198.97 | 2019-2021 | |
| Lilly USA, LLC | $190.27 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $165.34 | 2019-2021 | |
| Abbott Laboratories | $150.40 | 2021-2024 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $113.95 | 2019-2021 | |
| Allergan, INC. | $88.75 | 2019-2020 | |
| Genentech USA, INC. | $88.46 | 2019-2020 | |
| Dexcom, INC. | $58.95 | 2021 | |
| Sunovion Pharmaceuticals INC. | $56.06 | 2019 | |
| Eisai INC. | $52.79 | 2020 | |
| Ironwood Pharmaceuticals, INC | $34.29 | 2019-2021 | |
| Esperion Therapeutics, INC. | $23.10 | 2021 | |
| Mylan Specialty L.P. | $21.66 | 2019 | |
| Ironshore Pharmaceuticals INC. | $17.16 | 2019 | |
| Sun Pharmaceutical Industries INC. | $16.31 | 2021 | |
| Kyowa Kirin, INC. | $15.06 | 2020 | |
| Hologic Sales and Service, LLC | $14.79 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.93 | 2019 | |
| Jazz Pharmaceuticals INC. | $12.84 | 2021 | |
| Antares Pharma, INC. | $12.69 | 2021 | |
| Boston Scientific Corporation | $12.29 | 2020 | |
| Shire North American Group INC | $11.65 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.64 | 2020 | |
| Almatica Pharma LLC | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.